

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

NEW TARGET ANTI-TUMOR DRUG “SYHA1801” WAS GRANTED CLINICAL TRIAL APPROVAL

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that “SYHA1801” (the “**Product**”) developed by CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.* (石藥集團中奇製藥技術(石家莊)有限公司), a subsidiary of the Group, was granted approval by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. The Product has a number of patent applications in China and overseas.

The Product is a new type of small-molecule kinase inhibitor and currently there is no product of the same type available in the global market. The potential indications of the Product are advanced solid tumors. The pre-clinical studies indicated that the Product has an outstanding efficacy in respect of in vitro and in vivo anti-tumor activity and good safety, providing a promising prospect of demonstrating good efficacy for the anti-cancer treatment in the clinical trials.

Given the favorable results of the non-clinical studies, the Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible for the benefit of patients around the world.

* *for identification purpose only*

By Order of the Board
CSPC Pharmaceutical Group Limited
Cai Dongchen
Chairman

Hong Kong, 21 August 2019

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LU Hua, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.